Credit Suisse Ag Genmab A/S Transaction History

Credit Suisse Ag

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$33.8 - $47.06 $327,724 - $456,293	-9,696 Reduced 46.54%	11,136 $471,000
Q3 2022 Nov 10, 2022	SELL	$31.52 - $373.61 $647,420 - $7.67 Million	-20,540 Reduced 49.65%	20,832 $669,000
Q2 2022 Aug 12, 2022	SELL	$26.83 - $38.57 $178,848 - $257,107	-6,666 Reduced 13.88%	41,372 $1.34 Million
Q1 2022 May 16, 2022	SELL	$30.95 - $39.68 $666,663 - $854,707	-21,540 Reduced 30.96%	48,038 $1.74 Million
Q4 2021 Feb 14, 2022	BUY	$35.87 - $47.12 $200,800 - $263,777	5,598 Added 8.75%	69,578 $2.75 Million
Q3 2021 Nov 12, 2021	BUY	$41.55 - $48.72 $449,986 - $527,637	10,830 Added 20.38%	63,980 $2.8 Million
Q2 2021 Aug 16, 2021	SELL	$32.88 - $44.57 $6.74 Million - $9.13 Million	-204,927 Reduced 79.41%	53,150 $2.17 Million
Q1 2021 May 14, 2021	BUY	$30.92 - $44.4 $7.98 Million - $11.5 Million	258,077 New	258,077 $8.47 Million

240

52.6M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $14.6B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.